CaliciPro™ – Terapia antiviral para la estomatitis por calicivirus felino

CaliciPro™ – EIDD-1931 Oral Capsules (15 mg)

Antiviral agent for feline calicivirus–associated stomatitis and oral inflammatory disease

For veterinary use only

Active Ingredient

• EIDD-1931 (β-D-N4-hydroxycytidine) – 15 mg per capsule

• Pharmacologically equivalent to >60 mg molnupiravir (EIDD-2801)

IndicationsCaliciPro™ is intended for the management of severe oral inflammatory diseases driven by chronic or high-load FCV infection, including:

Primary Indications

• Feline Chronic Gingivostomatitis (FCGS)– particularly cases with confirmed or suspected calicivirus involvement

• Juvenile Onset Gingivitis/Stomatitis

• Caudal Stomatitis

• Ulcerative Stomatitis

• Viral Glossitis & Lingual Ulceration

• Buccal, Labial & Palatal Ulcers of Viral Origin

Clinical Signs

• Oral pain, reluctance to eat

• Ptyalism (drooling)

• Halitosis

• Dysphagia

• Mucosal ulceration

• Gingival bleeding

• Weight loss / poor body condition due to oral discomfort

CaliciPro™ may be used as primary antiviral therapy or as part of a multimodal treatment plan (e.g., analgesia, dental care, antibiotics for secondary infection).

Mechanism of ActionEIDD-1931 is the active intracellular metabolite of molnupiravir.

Once absorbed, it is phosphorylated to its triphosphate form and incorporated into viral RNA by RNA-dependent RNA polymerase (RdRp), causing:

• Lethal mutagenesis

• Rapid decline in viral replication

• Reduced viral load within mucosal tissues

Compared with EIDD-2801, CaliciPro's EIDD-1931 demonstrates:

• Higher intrinsic antiviral potency

• More predictable pharmacokinetics

• No requirement for enzymatic conversion from prodrug form

Reference potency data shows EIDD-1931 is 4.4x - 10× more potent than molnupiravir.  

Reference: ht​​​tps://pmc.ncbi.nlm.nih.gov/articles/PMC9227765/

Treatment Duration:4–12 weeks depending on lesion severity, clinical response, and relapse risk.

Combination therapy:

Often paired with:

• Analgesics (e.g., meloxicam)

• Doxycycline for secondary bacterial overgrowth

• Chlorhexidine oral care

• Nutritional support / appetite stimulants

Pharmacokinetics

• High oral bioavailability in felines

• Rapid intracellular activation

• Excellent distribution into oral mucosa, gingival tissues, and saliva

• Stable therapeutic levels with BID dosing

• Lower mg/kg requirement due to high potency

• Safety Profile

Contraindications:

1. Pregnant or breeding cats (theoretical mutagenicity risk)

2. Severe hepatic impairment

3. Caution in renal insufficiency if combined with NSAIDs

Monitoring:For extended therapy (>6 weeks):

• CBC every 2–4 weeks

• ALT/AST if concurrent medications used

• Body weight and pain scoring

Adverse effects are typically mild and dose-dependent (GI upset, transient lethargy).

Clinical ExpectationsVeterinarians may expect improvement in:

1. Drooling and oral pain within 3–7 days

2. Ulcer depth reduction within 1–2 weeks

3. Appetite return and weight gain within 2–3 weeks

4. Mucosal healing and inflammation reduction over 4–12 weeks

Best outcomes are seen when FCV involvement is confirmed or strongly suspected.

All orders are processed and dispatched within 24 hours using secure, tamper-evident, and discreet packaging to safeguard product integrity during transit.

We offer fast domestic and international delivery to most destinations across the Europe, GCC, Asia, North America, and South America, with typical delivery times of 2–5 business days.

For destinations that require international shipping, shipments are handled by DHL and FedEx for maximum reliability and tracking accuracy.

Domestic deliveries are fulfilled through trusted local express couriers to ensure prompt arrival.

Casos leves (úlceras tempranas, gingivitis juvenil, irritación bucal viral leve) a casos moderados (gingivoestomatitis con molestias al comer, babeo, ulceración moderada): Use CaliciPro™

Casos graves (FCGS, estomatitis caudal, ulceración extensa, dolor intenso, anorexia): Use CaliciPro™ Max

Instrucciones de dosificación:

Menos de 2.5 kg, 1 cápsula cada 12 horas

2.5 kg ~ 5 kg, 2 cápsulas cada 12 horas

Más de 5 kg, 3 cápsulas cada 12 horas

Ejemplo 1: Luna pesa 4.5 kg, tiene gingivitis juvenil, con encías de color rojo brillante. Use CaliciPro™, 2 cápsulas, cada 12 horas. Ejemplo 2: Spark pesa 3.3 kg, tiene estomatitis y experimenta dolor de moderado a intenso. Use CaliciPro™ Max, 2 cápsulas, cada 12 horas.

Cada cápsula de CaliciPro™ contiene 15 mg de EIDD-1931.

Cada cápsula de CaliciPro™ Max contiene 30 mg de EIDD-1931.

Si se producen vómitos dentro de los 30 minutos, administre otra dosis completa.

Duración del tratamiento: 

• Leve: 4–6 semanas

• Moderado: 6–8 semanas

• FCGS grave: 8–12+ semanas

Ajuste la dosis según los signos clínicos. Signos de subdosificación:

• Babeo persistente

• Dolor al masticar

• Curación lenta de úlceras

• Pérdida de peso

Aumente la dosis dentro del rango recomendado solo bajo dirección veterinaria.

Almacenamiento: Almacenar en un lugar fresco y seco, lejos de la luz solar.

Presentación: 60 cápsulas envasadas en una bolsa de mylar sellada al vacío.

Caducidad: 12 meses a partir de la fecha de producción impresa en el paquete.

Relapse is Possible – Plan for Maintenance

Even with successful initial treatment, 20-30% of cats experience relapses.

Why relapses happen:

• FCV can persist in tissues even after viral suppression

• Stress, illness, or immune system changes can trigger reactivation

• Some cats are genetically prone to chronic FCV

Maintenance strategies to prevent relapse:

Option A: Continuous Low-Dose

• After 12-16 weeks at full dose, reduce to half of previous dosage.

• Continue indefinitely

• Most cost-effective for cats with frequent relapses

Option B: Intermittent Courses

• Stop after 12-16 weeks

• Monitor closely

• At first sign of relapse (mild drooling, reduced appetite), restart 4-6 week course

• Some cats do well with this approach (2-3 courses per year)

Option C: Seasonal/Stress-Triggered

• Some cats relapse during specific triggers (boarding, moving, new pets, illness)

• Use CaliciPro™ Max preventively during high-stress periods

Early relapse warning signs:

• Increased drooling (even if mild)

• Slight decrease in appetite

• Pawing at mouth occasionally

• Bad breath returning

• Gum redness reappearing

Act quickly: Restart treatment at first signs = easier to control than waiting until severe relapse.

• ⚠️ EIDD-1931 has potential teratogenic effects (can harm developing kittens).

  Absolutely do NOT use in:

  • Pregnant queens (any stage of pregnancy)

  • Nursing queens (drug may pass into milk)

  • Breeding cats attempting to conceive

  If your cat is:

  • Female and not spayed → spay before starting treatment or ensure no breeding exposure

  • Already pregnant → do not use CaliciPro™ Max, discuss alternatives with vet

  • Nursing → wait until kittens are weaned (8-10 weeks)

  Male cats:

  • Limited data on effects on sperm/fertility

  • Use with caution in breeding males

  • Consider temporary contraception if female cats in household

  
  

CaliciPro™ can generally be used alongside other medications, but be aware:

✅ Safe to combine:

• Antibiotics (amoxicillin, clindamycin, azithromycin)

• Pain medications (gabapentin)

• Appetite stimulants (mirtazapine, maropitant)

• Vitamin B12

• Probiotics

• Most chronic disease medications (thyroid, blood pressure)

⚠️ Use with caution (vet supervision required):

• NSAIDs (meloxicam, robenacoxib) – monitor kidney function closely

• Steroids (prednisolone, dexamethasone) – can use short-term, but taper as CaliciX™ works

• Chemotherapy drugs – potential additive bone marrow suppression

• Immunosuppressants (cyclosporine) – may reduce effectiveness of immune response needed to clear virus

❌ Avoid:

• Ribavirin (another antiviral) – redundant mechanism, increased toxicity risk

• Other experimental antivirals without vet guidance

If your cat is on multiple medications, provide complete list during consultation.